Sino Biopharmaceutical (HKG:1177) has enrolled the first patient in a phase 1 clinical trial in China for tumor drug LM-2417, developed by unit LaNova Medicines, a Tuesday Hong Kong bourse filing said.
The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of the drug as monotherapy or in combination with other anti-tumor drugs in patients suffering from advanced malignant solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.